APA (7th ed.) Citation

B, M., M, L., M, S., TC, S., P, M., B, F., . . . A, D. (2020). Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer. Breast cancer research and treatment, 183(2), 411. https://doi.org/10.1007/s10549-020-05793-1

Chicago Style (17th ed.) Citation

B, Moftakhar, Lekkala M, Strawderman M, Smith TC, Meacham P, Fitzgerald B, Falkson CI, and Dhakal A. "Impact of Early Dose Intensity Reduction of Palbociclib on Clinical Outcomes in Patients with Hormone-receptor-positive Metastatic Breast Cancer." Breast Cancer Research and Treatment 183, no. 2 (2020): 411. https://doi.org/10.1007/s10549-020-05793-1.

MLA (9th ed.) Citation

B, Moftakhar, et al. "Impact of Early Dose Intensity Reduction of Palbociclib on Clinical Outcomes in Patients with Hormone-receptor-positive Metastatic Breast Cancer." Breast Cancer Research and Treatment, vol. 183, no. 2, 2020, p. 411, https://doi.org/10.1007/s10549-020-05793-1.